MACK · Merrimack Pharmaceuticals Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $669.0K | - | $531.0K | $569.0K | $586.0K | - | $504.0K | $486.0K | $577.0K | - |
| Total Operating Expenses | $669.0K | - | $531.0K | $569.0K | $447.0K | - | $504.0K | $486.0K | $132.0K | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($669.0K) | - | ($531.0K) | ($569.0K) | ($447.0K) | - | ($504.0K) | ($486.0K) | ($132.0K) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | $201.37M | - | ($279.0K) | ($391.0K) | ($271.0K) | - | ($442.0K) | ($478.0K) | ($132.0K) | - |
| EPS - Basic | $13.93 | - | ($0.02) | ($0.03) | ($0.02) | - | ($0.03) | ($0.04) | - | - |
| EPS - Diluted | $13.93 | - | ($0.02) | ($0.03) | ($0.01) | - | ($0.03) | ($0.04) | - | - |
Balance Sheet
| Line item | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $234.16M | $5.99M | $6.08M | $10.13M | $19.40M | $19.44M | $13.09M | $13.36M | $14.29M | $14.20M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $168.0K | $74.0K | $111.0K | $80.0K | $89.0K | $188.0K | $67.0K | $84.0K | $177.0K | $120.0K |
| Current Assets | $244.32M | $19.18M | $19.29M | $19.44M | $19.63M | $19.83M | $13.63M | $14.04M | $14.61M | $14.68M |
| Total Assets | $244.32M | $19.19M | $19.30M | $19.45M | $19.64M | $19.84M | $13.64M | $14.05M | $14.64M | $14.75M |
| Current Liabilities | $22.67M | $441.0K | $493.0K | $411.0K | $463.0K | $589.0K | $448.0K | $441.0K | $564.0K | $562.0K |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $22.67M | $441.0K | $493.0K | $411.0K | $463.0K | $589.0K | $448.0K | $441.0K | $564.0K | $562.0K |
| Stockholders' Equity | $221.65M | $18.75M | $18.81M | $19.04M | $19.17M | $19.25M | $13.19M | $13.61M | $14.07M | $14.19M |
| Retained Earnings | ($347.45M) | ($548.82M) | ($548.58M) | ($548.30M) | ($547.91M) | ($547.64M) | ($547.14M) | ($546.70M) | ($546.22M) | ($546.09M) |
Cash Flow
| Line item | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.31M) | - | - | - | ($356.0K) | - | - | - | ($354.0K) | - |
| Investing Cash Flow | $228.00M | - | - | - | $139.0K | - | - | - | $445.0K | - |
| Financing Cash Flow | $1.49M | - | - | - | $179.0K | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | 82.4% | - | -1.4% | -2.0% | -1.4% | - | -3.2% | -3.4% | -0.9% | - |
| Return on equity | 90.9% | - | -1.5% | -2.1% | -1.4% | - | -3.4% | -3.5% | -0.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 10.78 | 43.50 | 39.14 | 47.30 | 42.39 | 33.66 | 30.42 | 31.85 | 25.91 | 26.13 |
| Quick ratio | 10.78 | 43.50 | 39.14 | 47.30 | 42.39 | 33.66 | 30.42 | 31.85 | 25.91 | 26.13 |
| Cash ratio | 10.33 | 13.58 | 12.34 | 24.65 | 41.90 | 33.00 | 29.22 | 30.28 | 25.34 | 25.27 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.10 | 1.02 | 1.03 | 1.02 | 1.02 | 1.03 | 1.03 | 1.03 | 1.04 | 1.04 |
| Liabilities / Assets | 0.09 | 0.02 | 0.03 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -49.7% | - | -5.4% | -17.1% | -238.6% | - | 4.0% | 37.5% | 81.0% | - |
| Net income growth (YoY) | - | - | 36.9% | 18.2% | -105.3% | - | 15.8% | 37.0% | 81.0% | - |
| EPS growth (YoY) | - | - | 33.3% | 25.0% | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 1056.1% | -2.6% | 42.6% | 39.8% | 36.2% | 35.7% | -9.8% | -9.8% | -10.7% | -11.4% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing MERRIMACK PHARMACEUTICALS INC against the 5 most active filers in the same SIC group.